Articles

Find an Article

Filter articles

Applied Filters

Showing 61 to 70 of 314 results

LSIPR 50 2018: Personalised medicine: the way forward

US13-07-2018

BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.

LSIPR 50 2018: Leading the transformation change

US12-07-2018

Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.

LSIPR 50 2018: The promise of IP

US11-07-2018

Since joining Eli Lilly’s patent division nearly 20 years ago, Manisha Desai has worked on the procurement and enforcement of patents worldwide.

Plant patents in Mexico: uncertainty ahead

Mexico10-07-2018Daniel Eduardo López and Esteban Rodríguez

A shift in Mexico’s examination practice on plant-related patents has caused legal uncertainty, say Daniel Eduardo López and Esteban Rodríguez of Clarke Modet & Co.

LSIPR 50 2018: It’s not like selling cars

US04-07-2018

Balancing a company’s duty to shareholders with the public responsibility to provide lifesaving treatments is a constant challenge, as Issi Rozen, chief business officer at the Broad Institute of MIT and Harvard, tells LSIPR.

LSIPR 50 2018: Big changes in Brazil

Brazil03-07-2018

With his interests in IP development, biotechnology innovation policy, and R&D, Luiz Otávio Pimentel, president of Brazil’s patent office, tells LSIPR of his aims to improve the country’s IP performance.

The future of precision medicine part 1: challenges and opportunities

UK, US13-06-2018Daniel Lim

The healthcare industry and governments around the world are turning to precision medicine as an opportunity and a potential saviour. Daniel Lim of Kirkland & Ellis discusses the issues around translating the promise of precision medicine into real world clinical practice.

Protecting patients, and patents

Canada, Indonesia, Singapore04-06-2018

Drug companies can take heart from a range of best practices in the battle against counterfeit medicines, as LSIPR finds out.

Regulation and licensing: the CRISPR conundrum continues

China, EU, US04-06-2018

As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.

ZFN: a rival to CRISPR

US04-06-2018

As a rival to CRISPR in the gene-editing field, zinc finger nuclease technology is making a name for itself. LSIPR hears from Sandy Macrae, CEO of Sangamo Therapeutics, one of the key players in this area.

Showing 61 to 70 of 314 results

LSIPR